The effect of Lorazepam on the anxiety of heart attack patients

The short-term effect of lorazepam on the anxiety level of ST Elevation Myocardial Infarction (STEMI) patients candidate for Primary Percutaneous Coronary Intervention (PPCI)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201102049232N3

Enrollment

140

Registered

2023-01-10

Start date

2023-01-21

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: STEMI. Condition 2: Anxiety. ST elevation (STEMI) myocardial infarction of unspecified site Anxiety disorder, unspecified

Interventions

Intervention 1: Intervention group: Patients in this group receive a single dose of 1 mg/dl lorazepam from Kimidaro pharmaceutical company half an hour before Primary Percutaneous Coronary Interventio

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ST Elevation Myocardial Infarction (STEMI) patients candidate for Primary Percutaneous Coronary Intervention (PPCI)

Exclusion criteria

Exclusion criteria: Patients who cannot take lorazepam because of Drug interactions, including alcohol; barbiturates; antipsychotics sedatives; hypnotics; anxiolytics; opioids; antidepressants; narcotics; analgesics; sedatives; antihistamines; anticonvulsants and anesthetics. Patients who cannot take lorazepam because of lorazepam Contraindications including Allergy to Lorazepam; acute angle; closure glaucoma; severe respiratory depression and sleep apnea Patients who cannot take lorazepam because of unconsciousness

Design outcomes

Primary

Measure	Time frame
Anxiety. Timepoint: First ward visit after Primary Percutaneous Coronary Intervention (PPCI). Method of measurement: Hospital Anxiety and Depression Scale (HADS) questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Pazoki

Qazvin University of Medical Sciences

a.pazoki@qums.ac.ir+98 28 3332 6034

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026